# Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes

> **NCT03579160** · PHASE2,PHASE3 · TERMINATED · sponsor: **Brigham and Women's Hospital** · enrollment: 10 (actual)

## Conditions studied

- Wound of Skin
- Wound Heal
- Surgical Wound
- Full Thickness Skin Graft Healing

## Interventions

- **DRUG:** 0.25% timolol gel with full-thickness skin grafts
- **OTHER:** Vaseline dressing

## Key facts

- **NCT ID:** NCT03579160
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-02
- **Primary completion:** 2022-01-10
- **Final completion:** 2022-01-10
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Due to the insufficient accrual rate and strategic reasons to focus our efforts on higher impact research projects.
- **Last updated:** 2022-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03579160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03579160, "Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03579160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*